Huifeng said that the order is valued at approximately $3.8m with shipments between August 2010 and July 2011.
Diosmin, a flavonoid that can be isolated from various plant sources or derived from the flavonoid hesperidin, is used as a pharmaceutical material as a supplement to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins.
Jing’an Wang, CEO of Huifeng Bio-Pharmaceutical Technology, said: “I am excited to share news of this purchase order with our investors. Huifeng Bio-Pharmaceutical Technology has obtained GMP certification and applied for the Certification of Suitability to Monograph of European Pharmacopoeia (COS) from the European directorate for the quality of medicine.
“Once the company receives COS approval, we believe that the company will continue to expand its market share.”